Author details

Full Name

Richard A Scolyer

Affiliation

ORCID

Career Start Year

1999

Papers

728

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37714220	Prognosis for people with multiple primary melanomas compared with a single primary melanoma.		2024
36916530	Lentigo maligna and lentigo maligna melanoma in young patients in Australian tertiary centres.		2023
36251355	Clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis.	Journal of the European Academy of Dermatology and Venereology	2023
36174713	Hypoxia Controls the Glycome Signature and Galectin-8-Ligand Axis to Promote Protumorigenic Properties of Metastatic Melanoma.		2023
36166093	Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.	Clin Cancer Res	2023
36400594	Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma.	Pathology	2023
37606856	Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.		2023
37951732	Affecting change as a clinical academic.		2023
37938819	Perspectives and Strategies to Minimize Harm From Melanoma Diagnosis.		2023
37910123	Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma.		2023
37808404	Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies.		2023
37728525	Online tools for predicting melanoma survival: Including sentinel node status as a variable improves prediction accuracy.		2023
37894379	VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types-A Meta-Analysis.		2023
37573165	Implementing structured pathology reporting protocol for non-melanocytic skin cancers: practical considerations.		2023
37573162	Looking beyond workforce parity: addressing gender inequity in pathology.	Pathology	2023
37966706	Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.		2023
37789011	Uncovering the complex relationship between balding, testosterone and skin cancers in men.	Nat Commun	2023
37865395	Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies.		2023
37775188	Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial.	Lancet Digit Health	2023
37286471	Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma.		2023
36840895	A sheep in wolf's clothing: Agminated blue naevi masquerading as in-transit melanoma metastases.		2023
37285137	Melanoma In Situ-Getting the Diagnosis and Prognosis Right.		2023
36653238	Interobserver agreement in the histopathological classification of desmoplastic melanomas.		2023
37149545	Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma.	Ann Surg Oncol	2023
36509217	Melanomas in children and adolescents: Clinicopathologic features and survival outcomes.	J Am Acad Dermatol	2023
36646575	Representativeness of initial skin biopsies showing pure desmoplastic melanoma: implications for management.		2023
36762595	Development and validation of risk calculators for people with "thin" melanomas on their skin to predict the likelihood that their cancer will return: a plain language summary of publication.	Future Oncol	2023
37393148	Inter-rater concordance of basal cell carcinoma subtypes: influences on reporting format and opportunities for further classification modifications.		2023
37074717	Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma.		2023
36947065	Junctional Nevus and Early Melanoma on Sun-Damaged Skin of the Head/Neck: a Clinico-Pathologic Challenge.		2023
36635156	Biology and genetics of acquired and congenital melanocytic naevi.		2023
37263897	External validation in an Australian population of the EORTC-DeCOG nomogram predicting recurrence, distant metastasis and overall mortality in melanoma patients with positive sentinel lymph nodes.		2023
37196312	Effect of Histopathological Explanations for Dermoscopic Criteria on Learning Curves in Skin Cancer Training: a Randomized Controlled Trial.		2023
36946230	Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.		2023
37193799	Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.	Nat Med	2023
36630138	Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement.	JAMA Netw Open	2023
36477181	Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.	Clin Cancer Res	2023
36935017	Reply to: "Estrogen could also play a key role in the development of pediatric melanoma".		2023
36934113	The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.		2023
37055772	Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach.		2023
36736995	IFN-Î³ Signaling Sensitizes Melanoma Cells to BH3 Mimetics.		2023
36681299	Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.		2023
37104746	Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.		2023
36856616	Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.		2023
36855833	In vivo reflectance confocal microscopy can detect the invasive component of lentigo maligna melanoma: Prospective analysis and case-control study.		2023
36790412	Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy.	Clin Cancer Res	2023
37353974	The association of dermatologist demographic density with melanoma survival in New South Wales, Australia.		2023
36920329	IFN-Î³ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.	J Exp Med	2023
36788083	Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets.		2023
37534694	Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose.		2023